 Verastem Oncology Inc NASDAQ: VSTM entered into a credit facility with Oxford Finance LLC for up to 150 million to primarily support the continued development, commercial preparation, and potential launches of VS-6766 and defactinib. Verastem drew an initial 25 million. 